Trial Profile

A Phase 2a, Double-blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of IRL201104 in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jan 2024 According to a Revolo Biotherapeutics media release, Based on the results from RVLO 121-04, the company plans to initiate a Phase 2b trial of 1104 in 2024,which will evaluate higher dose levels of 1104 and a longer duration of therapy.
30 Jan 2024 According to a Revolo Biotherapeutics media release, the company received Orphan Drug Designation from FDA to 1104 ,for eosinophilic esophagitis treatment.
30 Jan 2024 According to a Revolo Biotherapeutics media release,Evan Dellon is a Principal Investigator for the Phase 2a clinical trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com